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Although Duchenne muscular dystrophy is primarily classified as a neuromuscular disease, cardiac complications play an
important role in the course of this X-linked inherited disorder. The pathobiochemical steps causing a progressive decline in
the dystrophic heart are not well understood. We therefore carried out a fluorescence difference in-gel electrophoretic analysis
of 9-month-old dystrophin-deficient versus age-matched normal heart, using the established MDX mouse model of muscular
dystrophy-related cardiomyopathy. Out of 2,509 detectable protein spots, 79 2D-spots showed a drastic differential expression
pattern, with the concentration of 3 proteins being increased, including nucleoside diphosphate kinase and lamin-A/C, and
of 26 protein species being decreased, including ATP synthase, fatty acid binding-protein, isocitrate dehydrogenase, NADH
dehydrogenase, porin, peroxiredoxin, adenylate kinase, tropomyosin, actin, and myosin light chains. Hence, the lack of cardiac
dystrophin appears to trigger a generally perturbed protein expression pattern in the MDX heart, affecting especially energy
metabolism and contractile proteins.
1. Introduction
The identification of the gene responsible for the pri-
mary defect in X-linked muscular dystrophy [1] led to
the discovery of its protein product, the large membrane
cytoskeletal element dystrophin [2]. The full-length Dp427
isoform of dystrophin is almost completely missing from
the dystrophic surface membrane [3], which triggers the
characteristic dystrophic phenotype of progressive skeletal
muscle weakness and fibre wasting [4]. Mutations in the
dystrophin gene cause the most prevalent and lethal gender-
specific genetic disease of childhood, Duchenne muscular
dystrophy (DMD), and its more benign and less frequent
counterpart Becker’s muscular dystrophy, as well as X-
linked dilated cardiomyopathy [5]. Dystrophin forms a
supramolecular complex with various surface glycoproteins
[6] that are involved in cellular signaling, receptor clustering
and stabilization of the cellular periphery [7]. Tissue-specific
variations in dystrophin isoforms delegate the composition
and subcellular localization of the dystrophin-glycoprotein
complex, and hence the function of the specific mem-
brane assembly may vary between the brain, heart, and
skeletal muscles [8]. In muscular dystrophy, deficiency in
dystrophin causes a significant reduction in the surface-
associated glycoprotein complex, which severely impairs the
integrity of the sarcolemma [9] and causes a broad spectrum
of downstream alterations such as enhanced proteolytic
destruction of muscle proteins and abnormal Ca2+-handling
[10]. This classifies DMD primarily as a genetic disorder of
skeletal muscle, but pathological alterations are also present
in cardiac muscle and diaphragm, as well as the peripheral
and central nervous system [11].
The majority of DMD patients develop clinical cardiac
symptoms during the second decade of life [12], including
arrhythmias, cardiomyopathy, and regional wall abnormali-
ties, leading to fatal cardiac complications in about 20% of
cases [13]. On the cellular level, the gradual replacement of
cardiac fibres by connective and fatty tissue is a hallmark
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of the dystrophic heart [14]. While dystrophin-deficient
skeletal muscles undergo cycles of fibre degeneration and
regeneration, dystrophic heart fibres exhibit only a limited
regenerative capacity causing a progressive decline in the
cardiomyocyte population of the dystrophic heart [15].
Since cardiomyopathy is a frequent occurrence in inherited
muscular dystrophies [16], a number of novel therapeutic
approaches are tested to specifically address the cardiac
symptoms [17, 18], especially membrane-stabilizing agents
such as tri-block poloxamers [19]. In this study, we used
the X-linked muscular dystrophy (MDX) mouse, a well-
established animal model of DMD [20] that is missing
dystrophin isoform Dp427 [21]. Although the dystrophic
phenotype of young MDX hearts does not represent a
perfect replica of DMD-related cardiomyopathic complica-
tions [22], in aged MDX hearts the pathological changes
are of considerable clinical relevance [23–25] and cardiac
MDX fibres are frequently used to evaluate new treatment
strategies to counteract cardiomyopathic complications
[26–29].
The absence of cardiac dystrophin is clearly associated
with necrotic changes, extensive infiltration of inflammatory
cells, increase in adipose tissue, interstitial fibrosis, tachycar-
dia, and impaired contractile properties in the MDX heart
[22, 30, 31]. In analogy to DMD hearts, the expression of
dystrophin-associated glycoproteins is also greatly reduced
in dystrophin-deficient MDX heart cells [32]. Secondary
abnormalities in cardiac fibres from the MDX mouse include
the drastic reduction in key luminal Ca2+-binding proteins
[33] and abnormal stress-induced Ca2+-influx into the
cytosol [34]. Interestingly, both physical exercise and aging
seem to accelerate the dystrophic process in cardiac MDX
tissue [35, 36], whereby a recent study by Spurney et al. [37]
revealed that heart dysfunction was most prominent at 9
months of age. This makes this age group of MDX hearts a
suitable DMD model for investigating global changes in the
cardiac MDX protein complement and was therefore chosen
in this study.
The development of mass spectrometry-based pro-
teomics for the swift identification of proteins has decisively
enhanced the analytical capability of comparative biomedical
studies [38]. In addition, the introduction of fluorescent dyes
has drastically increased the total number of identifiable two-
dimensional spots, whereby fluorescence difference in-gel
electrophoresis (DIGE) can be considered one of the most
advanced biomedical tools for studying two different sets of
soluble protein complements [39]. DIGE analysis generates
highly reproducible findings due to greatly reduced gel-to-gel
variations [40]. We have therefore used this technique here
for the proteomic profiling of the dystrophic MDX heart.
The usefulness of proteomics for determining the biomarker
signature of animal disease models of muscular disorders has
recently been reviewed [41]. An important aspect of genetic
mouse models is that they show, due to their inbred status,
genetically much less interindividual differences than human
patients. Therefore, considerably fewer experimental repeats
are capable of producing meaningful proteomic data. With
respect to X-linked muscular dystrophy, proteomic studies
have mostly focused on MDX skeletal muscles and have
identified numerous biomarker candidates, such as adenylate
kinase [42], calsequestrin [43], regucalcin [44], and the small
stress protein cvHsp [45]. In general, dystrophic skeletal
muscles show an extremely perturbed protein expression
pattern. Although the initial pathobiochemical consequence
of a primary genetic abnormality in dystrophin is a severe
reduction in dystrophin-associated proteins, this seems to
result in a variety of downstream alterations in various
classes of muscle proteins involved in fibre contraction, chap-
erone function, ion homeostasis, cytoskeleton formation and
metabolism [41].
In contrast, relatively little is known about global alter-
ations in the dystrophic heart. Building on the recent findings
of a combined metabolomic and proteomic investigation
into dystrophin deficiency in cardiac muscle [46], this report
describes the detailed DIGE analysis of the expression levels
of fluorescently-tagged dystrophic versus normal cardiac
proteins using both pH 4–7 and pH 6–11 range gels.
Following the densitometric determination of the expression
pattern of 2,509 cardiac protein spots, mass spectrometry
identified 26 proteins being decreased, including various
myosin light chains, tropomyosin, actin, adenylate kinase,
creatine kinase, vimentin, ATP synthase, fatty acid binding-
protein, isocitrate dehydrogenase, NADH dehydrogenase,
myozenin, porin, and peroxiredoxin, and 3 proteins being
increased, including lamin-A/C and nucleoside diphosphate
kinase. These findings suggest that the loss in dystrophin
causes abnormalities in cardiac metabolism, the cellular
stress response, the cytoskeleton, and the contractile machin-
ery. In the future, these results will be useful for comple-
menting studies into the molecular mechanisms of muscular
dystrophy and for evaluating the effects of novel drugs,
genetic modifications, or cell-based therapies on disease
progression.
2. Materials and Methods
2.1. Materials. For gel electrophoretic analyses, analytical
grade chemicals and materials were purchased from Amer-
sham Biosciences/GE Healthcare, Little Chalfont, Bucking-
hamshire, UK (CyDye DIGE fluor minimal dyes Cy3 and
Cy5; 24 cm pH 4–7 and 18 cm pH 6–11 immobilized pH gra-
dient (IPG) strips; IPG buffer; iodoacetamide), Biorad Lab-
oratories, Hemel-Hempstead, Hertfordshire, UK (Laemmli-
type buffer system; protein molecular mass markers),
National Diagnostics, Atlanta, GA, USA (ultrapure Protogel
acrylamide stock solution), Cosmo Bio Company, Tokyo,
Japan (2D silver stain II kit), and Perbio Science, Northum-
berland, UK (Coomassie Brilliant Blue G-250). Protease
inhibitors and chemiluminescence substrate were obtained
from Roche Diagnostics (Mannheim, Germany). Sequenc-
ing grade-modified trypsin was purchased from Promega
(Madison, WI, USA). Nitrocellulose transfer stacks were
from Invitrogen (Carlsbad, CA, USA). Primary antibodies
were obtained from Abcam Ltd., Cambridge, UK (ab28172 to
prohibitin; ab36329 to isocitrate dehydrogenase; ab14734 to
porin isoform VDAC1; ab54824 to adenylate kinase isoform
AK1; ab5432 to ATP synthase, ab16915 to cardiac fatty acid
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binding protein), Sigma Chemical Company, Dorset, UK
(mAb NOQ7.5.4D to slow/cardiac myosin heavy chain; pAb
to laminin), Visionbiosystems Novocastra, Newcastle upon
Tyne, UK (mAb NCL-DYS1 against the Dp427 isoform of
dystrophin), Thermo Fisher Scientific Inc., Rockford, IL,
USA (mAb Rd301 to desmin) and Santa Cruz Biotech-
nology, Santa Cruz, CA, USA (sc27992 to succinate dehy-
drogenase). All secondary antibodies were purchased from
Chemicon International (Temecula, CA, USA). For confocal
microscopy, Superfrost Plus positively-charged microscope
slides were purchased from Menzel Glaesser (Braunschweig,
Germany). Optimum cutting temperature (OCT) com-
pound was from Sakura Finetek Europe B.V (Zoeterwoude,
Netherlands) and p-phenylenediamine (PPD)-glycerol was
purchased from Citifluor Ltd. (London, UK). MitoTracker
Red CMXRos dye and Alexa Fluor-conjugated secondary
antibodies were from Invitrogen Molecular Probes (Bio
Sciences Ltd., Dun Laoghaire, Ireland). The DNA binding
dye diamidino-phenylindole (DAPI) and all other chemicals
used were of analytical grade and purchased from Sigma
Chemical Company, Dorset, UK.
2.2. Dystrophic MDX Animal Model. Hearts from male 9-
month old C57 control mice and age-matched dystrophic
mdx mice were obtained through the Bioresource Unit of
NUI Maynooth and the Animal House of the University of
Bielefeld. Animals were kept under standard conditions and
all procedures were performed in accordance with German
and Irish guidelines on the use of animals for scientific
experiments. Mice were killed by cervical dislocation and
their hearts removed and snap-frozen [32]. As previously
demonstrated by immunoblotting, the MDX mouse cohort
used in this study lacks the 427 kDa isoform of cardiac
dystrophin and shows a drastic reduction in dystrophin-
associated glycoproteins, such as dystroglycans and sarcogly-
cans [32, 33].
2.3. Preparation of Total Heart Muscle. For the proteomic
profiling of crude cardiac extracts, three normal and three
age-matched dystrophic hearts were separately prepared by
washing with distilled water to remove excess blood. Muscle
tissue was pulverized by grinding in liquid nitrogen using a
mortar and pestle. Ground hearts were solubilized in lysis
buffer with the ratio 100 mg wet weight to 1 mL lysis buffer
consisting of 9.5 M urea, 2% CHAPS, 0.8% IPG buffer pH
3–10, 1% (w/v) DTT and protease inhibitors [45]. Samples
for DIGE analysis were placed in buffer containing only urea
and CHAPS. Samples were gently rocked for 30 minutes and
protein concentration was determined using the Bradford
assay system [47]. For immunoblot analysis samples were
placed into homogenization buffer (0.5 M Hepes pH 7.4,
200 mM EGTA, 10% (w/v) sucrose, 3 mM MgCl2, and
0.1% (w/v) NaN3). The buffer was supplemented with a
protease inhibitor cocktail to prevent protein degradation
[45]. Extracts were shaken at 4◦C on a Thermomixer from
Eppendorf (Hamburg, Germany) for 4 hours and then
centrifuged at 4◦C for 20 minutes at 20,000× g in an
Eppendorf 5417R bench centrifuge.
2.4. Difference in-Gel Electrophoretic Analysis. Potential dif-
ferences in the expression pattern of the soluble proteome
from normal and MDX cardiac muscle were analysed
using the fluorescence difference in-gel electrophoretic DIGE
technique [39], as recommended by Karp and Lilley [48].
The fluorescent dyes Cy3 and Cy5 were reconstituted as a
stock solution of 1 mM in fresh dimethylformamide, then
diluted to a 0.2 mM solution prior to use. Labeling was
performed with 200 pmols of Cy3 fluor dye per 25μg protein.
An internal pooled standard of every sample was prepared
with the Cy5 fluor. Labelled samples were then vortexed and
incubated for 30 minutes on ice in the dark. The reaction
was quenched with 10 mM lysine on ice for 10 minutes [49].
For isoelectric focusing, pH 6–11 IPG strips were rehydrated
for 12 hours in rehydration buffer (8 M Urea, 0.5% CHAPS,
0.2% DTT, and 0.2% ampholytes) with the addition of
1.2% (v/v) DeStreak rehydration solution (Amersham Bio-
sciences/GE Healthcare, Little Chalfont, Buckinghamshire,
UK). Sample and equal volumes of reducing lysis buffer
(9.5 M Urea, 2% CHAPS, 2% DTT, and 1.6% ampholytes)
were added by anodic cup loading. For pH 4–7 focusing, IPG
strips were in-gel rehydrated with sample and equal volumes
of reducing lysis buffer made up in rehydration buffer. The
strips were run on an Amersham IPGphor IEF system with
the following running conditions: 3500 V for 21.3 hours, a
3500 to 8000 V gradient over 10 minutes in, and 8000 V
for 2 hours. For first dimension separation in the pH 6–
11 range the following protocol was employed: 80 V for 4
hours, 100 V for 2 hours, 500 V for 1.5 hours, 1000 V for
1 hour, 2000 V for 1 hour, 4000 V for 1 hour, 6000 V for 2
hours, and finally 8000 V for 2.5 hours. Following isoelectric
focusing, the IPG strips were equilibrated for 20 minutes
firstly in buffer containing 6 M urea, 30% (w/v) glycerol,
2% (w/v) SDS, 100 mM Tris-HCl, pH 8.8 with the addition
of 100 mM DTT and subsequently for 20 minutes in buffer
supplemented with 0.25 M iodoacetamide [49]. Strips were
briefly washed in sodium dodecyl sulfate-containing running
buffer (125 mM Tris, 0.96 M glycine, 0.1% (w/v) SDS) and
placed on top of 12.5% (w/v) resolving gels. To seal the strip
gels, they were overlaid with the above-described running
buffer containing 1% (w/v) agarose. The separation of the
cardiac proteins was carried out in the second dimension
by standard SDS polyacrylamide gel electrophoresis using
the DodecaCell system from Bio-Rad Laboratories (Hemel
Hempstead, Herts., UK). Slab gels contained 50μg protein
per gel. Electrophoresis was carried out overnight for
approximately 18 hours in the dark at 1.5 V per 21 cm-gel
until the Bromophenol Blue tracking dye just ran off the
gel.
2.5. Protein Visualization and Data Analysis. Fluorescent
CyDye-labelled cardiac proteins were visualized using a
Typhoon Trio variable mode imager form Amersham Bio-
sciences/GE Healthcare (Little Chalfont, Bucks., UK). For
image acquisition, Cy5- and Cy3-labelled proteins were
scanned at a wavelength of λ = 650 nm and λ =
550 nm, respectively. Photomultiplier tube (PMT) values
were optimised so that the volume of the most abundant
spot was between 80,000 and 99,000 when scanned at
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a resolution of 100μm. This guaranteed that no spot would
be saturated on the gel, therefore interfering with accurate
analysis. The Cy3 images were then analysed using Pro-
genesis SameSpots software version 3.2.3 from NonLinear
Dynamics (Newcastle upon Tyne, UK) and normalised
against their corresponding Cy5 image. Gels were aligned
to the reference image. Following detection of spots, the
gels were placed into groups (MDX versus normal) and
analysed to determine significant differences in 2D spot
abundance. An ANOVA score of 0.5 was required for spots
to be included in the subsequent analysis. Then principal
component analysis (PCA) was verified with changes dis-
playing power of <0.8 being removed from the analysis.
All remaining changed spots that met the significance
criteria were visually checked on the aligned gels to ensure
feasibility and were subsequently identified by LC-MS/MS
analysis.
2.6. Mass Spectrometric Identification of Cardiac Proteins.
Preparative gels containing 400 μg of protein (1:1 MDX
to normal) were stained with the dye Ruthenium II
Bathophenanthroline Disulfonate Chelate (RuBPs) [50].
RuBPs-stained gels were scanned at a wavelength of λ =
550 nm using the criteria outlined above. Prior to iden-
tification via LC-MS/MS technology, 2D protein spots of
interest were excised using the automated Ettan spot picker
system from Amersham Biosciences (Little Chalfont, Bucks.,
UK). Spots were digested as outlined by Shevchenko et al.
[51]. Briefly, gel pieces were destained before the addition
of 400 ng trypsin per spot, incubated for 30 minutes at 4◦C
before being digested overnight at 37◦C. 100 μL of extraction
buffer (1:2 v/v of 5% formic acid/acetonitrile) was added
to the peptides and incubated for 15 minutes at 37◦C.
All supernantant was then transferred into fresh tubes and
extracts were dried down completely in a vacuum centrifuge.
Peptides were reconstituted in 12 μL of 0.1% formic acid,
vortexed, sonicated, and the mixture was centrifuged for
20 minutes in cellulose spin filter tubes to remove any
gel particles. The remaining solution was placed into LC-
MS vials. Samples were analysed on an Agilent 6340 Ion
Trap LC mass spectrometer using electrospray ionization
(Agilent Technologies, Santa Clara, CA, USA) on a 10-
minute gradient of 5–100% acetonitrile/0.1% formic acid
with a post run of 1 minute [52]. Separation of peptides
was performed with a nanoflow Agilent 1200 series system,
equipped with a Zorbax 300 SB C18 μm, 4 mm 40 nl pre-
column. Mobile phases used were A: 0.1% formic acid, B:
90% acetonitrile and 0.1% formic acid. Samples (8μL) were
loaded onto the enrichment column with capillary flow rate
set at 4μL/min with a mix of A : B at a ratio of 19 : 1.
Elution was carried out with the nano pump flow rate set
at 0.6 μl/minute. Database searches were carried out using
Mascot MS/MS Ion search. Criterion for each search was
set at (i) species Mus musculus, (ii) two missed cleavages by
trypsin, (iii) variable modification: oxidation of methioine,
(iv) fixed modification: carboxymethylation of cysteines, and
(v) mass tolerance of precursor ions ±2Da and product ions
±1Da.
2.7. Immunoblot Analysis. In order to verify changes in the
expression of select cardiac proteins, 1-D gel electrophoresis,
Coomassie staining and immunoblotting was performed as
previously described in detail [32]. Gels were transferred
to an “iblot” transfer unit from Invitrogen (Carlsbad, CA,
USA) for semi-dry blotting. Electrophoretic transfer was
carried out for 6 min. Blocking of nitrocellulose sheets was
achieved with a milk protein solution (5% (w/v) fat-free milk
powder in 0.9% (w/v) NaCl, 50 mM sodium phosphate, pH
7.4) for 1 hour. Incubation with sufficiently diluted primary
antibody was carried out overnight with gentle agitation.
Nitrocellulose sheets were washed and then incubated for
1 hour with secondary peroxidase-conjugated antibodies,
diluted in blocking solution. Immuno-decorated bands were
visualized by the enhanced chemiluminescence method
using BM Chemiluminescence Blotting substrate from Roche
Diagnostics (Mannheim, Germany). Densitometric scanning
of immunoblots was performed on a Molecular Dynamics
300 S computing densitometer (Sunnyvale, CA, USA) with
ImageJ (NIH, USA) and GraphPad Prism (San Diego, CA,
USA) software.
2.8. Confocal Microscopy. For the localization of nuclei,
mitochondria and select marker proteins, confocal micro-
scopy was used as previously described in detail [45].
Normal and dystrophic MDX hearts were mounted on
cyrocassettes at −20◦C and transverse cryosections of 10 μm
thickness were cut on a Shandon Cryotome (Life Sciences
International, Cheshire, UK). Unfixed tissue sections were
transferred to Superfrost Plus positively-charged microscopy
slides. For labeling of mitochondria, freshly cut tissue
sections were incubated with a 1 : 100 diluted solution
of MitoTracker Red Chloromethyl-X-Rosamine (CMXRos)
dye for 30 minute, briefly washed in phosphate-buffered
saline and then immediately examined by microscopy [53].
CMXRos is a well-established lipophilic cationic fluorescent
dye that is highly specific for mitochondria [54] and is
routinely used to measure mitochondrial function and
morphology in cell culture and in whole tissues [55]. For
immunofluorescence microscopy, cryosections were briefly
fixed in ice-cold acetone for 5 minutes, followed by sub-
mersion in blocking solution (0.2% (w/v) bovine serum
albumin, 0.2% (v/v) Triton X-100, and 2.5% (v/v) goat
serum in phosphate-buffered saline) for 30 minute, and
then incubated with primary antibodies diluted in 0.2%
(w/v) bovine serum albumin and 0.2% (v/v) Triton X-100
in phosphate-buffered saline for 4 hours. Tissue sections
were washed twice for 30 minute in above solution omitting
antibodies and then labelled with secondary antibodies for
1 hour, followed by the above described washing procedure.
In order to determine the number of nuclei in normal
versus MDX hearts, cardiac tissue sections were labelled with
1μg/ml diamidino-phenylindole (DAPI) for 30 minute. One
drop of p-phenylenediamine (PPD)-glycerol was applied to
the immuno-decorated tissue sections and then coverslips
carefully placed over the sections, avoiding the introduction
of air bubbles. Fluorescent labelling patterns were visualised
with an Olympus IX81 microscope (Olympus Life and
Material Science Europe, Hamburg, Germany).
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3. Results
3.1. Comparative Proteomic Profiling of MDX Versus Normal
Heart Muscle. In contrast to non-fluorescent protein dye
methodology, comparative studies using fluorescent CyDyes
have an enhanced dynamic range of protein coverage [39].
DIGE analysis represents a highly accurate quantitative
technique that enables multiple protein samples to be
separated on the same two-dimensional gel. This reduces
the introduction of potential artifacts due to gel-to-gel
variations, making comparative DIGE approaches one of the
most powerful analytical tools for conducting comparative
biomedical investigations [40]. In order to determine global
changes in the heart due to deficiency in the dystrophin
isoform Dp427, we have carried out a DIGE analysis of
crude tissue extracts from 9-month old normal versus age-
matched dystrophic MDX mice. Due to the high cost of
breeding and maintaining mice to old age, as well as the
considerable cost of fluorescent tagging of large protein
populations, the number of biological repeats and analytical
DIGE gels was kept to a minimum. In order to satisfy
the statistical requirements for the generation of proper
proteomic data sets and perform an optimized DIGE analysis
of normal versus affected proteomes, we have followed the
recommendations by Urfer et al. [56] and Karp and Lilley
[48], respectively. In the first dimensional separation step via
isoelectric focusing, both a pH 4–7 and a pH 6–11 range were
employed to cover as many cardiac proteins with differing
charges as possible. Figure 1 illustrates the neutral and the
more acidic range of protein species and Figure 2 shows the
separation of neutral and more basic heart proteins. Shown
are representative two-dimensional gels of Cy3-labelled nor-
mal muscle (Figure 1(a); Figure 2(a), Cy3-labelled dystrophic
muscle (Figure 1(c); Figure 2(c) and corresponding Cy5-
labelled pooled standards (Figures 1(b),1(d); Figures 2(b),
2(d), which were analysed with the help of a Typhoon Trio
variable imager and Progenesis 2D analysis software. Overall,
2509 distinct protein species were recognized on the lower
and higher pH-range gels. Recently Raddatz et al. [57] have
catalogued the soluble murine heart protein complement.
The protein spot pattern presented here agrees in large parts
with their comprehensive 2D proteomic map of cardiac
tissue. Out of 2048 detectable protein spots on the pH 4–7
gels and 487 detectable protein spots on pH 6–11 gels, 79
protein spots showed a drastic differential expression pattern,
with 3 proteins being increased and 26 distinct protein
species being decreased. Electrospray ionization MS/MS
analysis was carried out to unequivocally identify the cardiac
proteins with a changed abundance in dystrophic heart
fibres.
3.2. DIGE Analysis of the Dystrophin-Deficient Heart. A list
of the cardiac protein species with a drastically altered
expression level in dystrophic MDX tissue is shown in
Table 1. The information on the 79 DIGE-identified protein
spots combine data from both pH 4–7 and pH 6–11 gels
and contain the spot number, protein name, protein ID,
number of matched peptides, percentage sequence coverage,
the relative molecular mass, pI-value, Mascot score and
fold-change of individual proteins affected by deficiency
in dystrophin. Since the MS-based analysis identified a
large number of matched peptide sequences, these data
are not shown. The majority of identified cardiac proteins
belonged to the main classes of metabolic or contractile
proteins. Components of the actomyosin apparatus, enzy-
matic and regulatory elements of mitochondria, glycolytic
enzymes, metabolic transporters, cellular stress proteins
and cytoskeletal components were clearly identified by MS
analysis. Cardiac proteins with a dystrophy-related change in
abundance ranged in molecular mass from apparent 14 kDa
to 90 kDa and covered a pI-range from approximately 5
to 9. DIGE Cy5 master gels of both the pH 4–7 and the
pH 6–11 range are shown in Figure 3(a), 3(b), so that it
is possible to correlate MS-identified protein species, listed
in Table 1, with distinct two-dimensional spots of altered
density in the dystrophic heart. An increased expression
level was shown for 3 cardiac proteins, that is, nucleoside
diphosphate kinase B (spot 1), the nuclear lamina matrix
protein lamin A/C (spot 2), and a component of the
electron-transferring flavoprotein dehydrogenase (spot 3).
All other identified protein species exhibited a decreased
abundance in dystrophin-deficient myocardial tissue. These
cardiac proteins are marked and numbered 4 to 79 in the
Cy5-labelled master gels of Figure 3. The protein species
with the highest decrease in concentration was identified
as the anti-oxidant enzyme peroxiredoxin-6 (spot 79). In
addition, mitochondrial ATP synthase (spots 50, 55, 69, 72,
73, 74, 77), isocitrate dehydrogenase (spot 38, 42), NADH
dehydrogenase (spot 40), pyruvate dehydrogenase (spots 11,
14, 15, 20, 25, 34), isovaleryl-CoA dehydrogenae (spots 8,
19), dienoyl-CoA isomerase (spot 17), oxoglutarate dehy-
drogenase (spot 7), prohibitin (spot 6), electron-transferring
flavoprotein (spots 5, 17), myozenin-2 (spot 4), voltage-
dependent anion-selective channel protein VDAC1 (spot
41), the slow/cardiac isoform of myosin light chain MLC2
(spots 26, 48, 62, 65, 70, 78), myosin light chain MLC3
(spots 53, 61, 76), cardiac alpha-actin (spots 21, 39, 45, 46,
56, 60, 64, 66, 67, 71, 75), alpha-1 tropomyosin (spots 35,
59), adenylate kinase AK1 (spot 68), creatine kinase (spot
16), cytochrome c oxidase (spots 22, 51), cytochrome b-
c complex (spots 10, 30, 57, 63), desmin (spot 43, 47, 52,
54, 58), vimentin (spots 12, 23), cardiac fatty acid binding-
protein FABP-3 (spots 27, 33, 49), heat shock protein Hsp27
(spot 18), heat shock protein Hsp60 (spots 31, 37, 44),
enolase (spots 13, 28, 32), DJ-1 protein (spot 29), valsolin-
containing protein VCP (spot 24), and albumin (spot 9)
were identified. The results for 2 decreased protein spots
have not been included in Table 1, since only 1 matched
peptide per cardiac protein could be determined by MS
analysis. It is international standard that proteomic studies
only list proteins with sequence coverage of less than 10%
when at least 2 separate matched peptide sequences are
available for an independent identification. The peptide
sequences LGANSLLDLVVFGR (2% sequence coverage)
and LTFDSSFSPNTGK (4% sequence coverage) identified
the nonlisted cardiac proteins as succinate dehydrogenase
(73.6 kDa; pI 7.1) and porin isoform VDAC1 (32.5 kDa; pI
8.6), respectively.
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Figure 1: 2D gel electrophoretic analysis of the dystrophic heart using the pH 4–7 range. Shown are Cy3-labelled gels of the soluble fraction
from normal (a) and dystrophic MDX (c) cardiac muscle, as well as Cy5-labelled gels containing pooled standards ((b), (d)). Representative
fluorescent DIGE gels with electrophoretically separated proteins are shown for the pH 4–7 range. The pH-values of the first dimension gel
system and molecular mass standards (in kDa) of the second dimension are indicated on the top and on the left of the panels, respectively.
3.3. Decreased Proteins in Dystrophic Heart Muscle. To illus-
trate representative examples of key cardiac proteins with
a drastically decreased expression in dystrophin-deficient
fibres, enlarged images of DIGE-identified protein spots are
shown in Figure 4. The direct comparison of fluorescently
labeled 2-D protein spots, which have been unequivocally
identified by mass spectrometric analysis (Table 1), shows the
cytosolic AK1 isoform of adenylate kinase, the mitochondrial
proteins ATPase synthase, porin isoform VDAC1, isocitrate
dehydrogenase, succinate dehydrogenase, and prohibitin, as
well as DJ1-protein, the stress protein Hsp60 and myosin
light chain isoform MLC2. A large proportion of the cardiac
proteins identified in this study by DIGE analysis belong to
the contractile apparatus, the cellular stress response and the
cytoskeletal network, as well as mitochondrial metabolism
including oxidative phosphorylation, the citric acid cycle and
fatty acid transportation.
3.4. Immunoblot Analysis of Dystrophic Heart Muscle. Pre-
vious studies have clearly shown that the deficiency in
dystrophin triggers a drastically reduced concentration of
the dystrophin-associated α/β-dystroglycan complex in the
MDX heart [32]. Immunoblotting has established dis-
tinct alterations down-stream of the cardiac dystrophin-
glycoprotein complex, such as the reduction in the luminal
Ca2+-binding proteins calsequestrin and sarcalumenin [33].
In analogy, we employed Western blotting here to verify
the results of our DIGE analysis by immuno-decoration
analysis of a select group of cardiac proteins. In this respect,
it is important to stress that the mass spectrometry-based
proteomic analysis of individual 2D spots identifies changes
in distinct subspecies of proteins and not alterations in the
total population of a protein isoform. The recent large-
scale cataloguing of the heart proteome has shown that
cardiac tissues contain thousands of different protein species,
whereby many proteins are represented by a large number
of distinct 2D-spots in analytical gels [57–59]. It is one
of the great advantages of modern proteomics that this
analytical approach can differentiate between differently
charged or sized subspecies of individual proteins. Since 1D
immunoblotting or immunofluorescence microscopy often
do not recognize all forms of a specific protein due to
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Table 1: List of DIGE-identified proteins with a changed abundance in 9-month old dystrophic MDX heart muscle.
Spot No. Protein name Protein ID
Peptides
matched
Coverage
(%)
Molecular
mass (kDa)
Isoelectric
point (pI)
Mascot score Fold change
1
Nucleoside
diphosphate
kinase B
NDKB MOUSE 4 34 17.5 6.9 69 4.4
2 Lamin-A/C LMNA MOUSE 4 6 74.5 6.5 111 1.9
3
Electron transfer
flavoprotein-
ubiquinone
oxidoreductase,
mitochondrial
ETFD MOUSE 8 15 68.9 7.3 45 1.8
4 Myozenin-2 MYOZ2 MOUSE 4 20 29.8 8.5 145 0.67
5
Electron transfer
flavoprotein subunit
alpha,
mitochondrial
ETFA MOUSE 2 12 35.3 8.6 89 0.67
6 Prohibitin PHB MOUSE 8 41 29.9 5.6 290 0.67
7
Dihydrolipoyllysine-
residue
succinyltransferase
component of
2-oxoglutarate
dehydrogenase
complex,
mitochondrial
ODO2 MOUSE 3 6 49.3 9.1 86 0.63
8
Isovaleryl-CoA
dehydrogenase,
mitochondrial
IVD MOUSE 7 23 46.7 8.5 89 0.59
9 Serum albumin ALBU MOUSE 3 5 70.7 5.8 82 0.59
10
Cytochrome b-c1
complex subunit
Rieske,
mitochondrial
UCRI MOUSE 4 13 29.6 8.9 84 0.56
11
Dihydrolipoyllysine-
residue
acetyltransferase
component of
pyruvate
dehydrogenase
complex,
mitochondrial
ODP2 MOUSE 10 20 68.5 8.8 117 0.53
12 Vimentin VIME MOUSE 11 20 53.7 5.1 118 0.53
13 Beta-enolase ENOB MOUSE 8 19 47.3 6.7 111 0.50
14
Pyruvate
dehydrogenase E1
component subunit
beta, mitochondrial
ODPB MOUSE 8 31 39.3 6.4 279 0.50
15
Pyruvate
dehydrogenase E1
component subunit
beta, mitochondrial
ODPB MOUSE 3 19 39.3 6.4 134 0.50
16 Creatine kinase
M-type
KCRM MOUSE 2 4 43.3 6.6 47 0.50
17
Delta(3,5)-
Delta(2,4)-dienoyl-
CoA isomerase,
mitochondrial
ECH1 MOUSE 4 24 36.4 7.6 201 0.50
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Table 1: Continued.
Spot No. Protein name Protein ID
Peptides
matched
Coverage
(%)
Molecular
mass (kDa)
Isoelectric
point (pI)
Mascot score Fold change
18 Heat shock protein
beta-1 Hsp27
HSPB1 MOUSE 2 8 23.1 6.1 50 0.50
19
Isovaleryl-CoA
dehydrogenase,
mitochondrial
IVD MOUSE 7 17 46.7 8.5 98 0.50
20
Pyruvate
dehydrogenase
protein X
component,
mitochondrial
ODPX MOUSE 5 11 54.3 7.6 63 0.48
21 Actin, alpha cardiac
muscle 1
ACTC MOUSE 6 19 42.3 5.2 104 0.48
22
Cytochrome c
oxidase subunit 5B,
mitochondrial
COX5A MOUSE 2 14 14.1 8.7 52 0.48
23 Vimentin VIME MOUSE 13 27 53.7 5.1 122 0.48
24
Transitional
endoplasmic
reticulum ATPase
(valosin-containing
protein VCP)
TERA MOUSE 5 10 89.9 5.1 171 0.46
25
Pyruvate
dehydrogenase E1
component subunit
beta, mitochondrial
ODPB MOUSE 4 14 39.3 6.4 100 0.44
26
Myosin regulatory
light chain 2,
ventricular/cardiac
muscle isoform
MLRV MOUSE 9 52 18.9 4.9 209 0.44
27
Fatty acid-binding
protein FABP-3,
heart
FABPH MOUSE 5 37 14.8 6.1 149 0.44
28 Enolase 1, alpha ENOA MOUSE 2 3 47.5 6.4 43 0.44
29 DJ-1 protein PARK7 MOUSE 4 26 20.2 6.3 90 0.44
30 Cytochrome b-c1
complex
QCR1 MOUSE 6 17 53.4 5.8 83 0.44
31
60 kDa heat shock
protein, Hsp60,
mitochondrial
CH60 MOUSE 2 6 61.1 5.9 63 0.42
32 Beta-enolase ENOB MOUSE 3 7 47.3 6.7 92 0.42
33
Fatty acid binding
protein, FABP-3,
heart
FABPH MOUSE 7 52 14.8 6.1 162 0.42
34
Pyruvate
dehydrogenase
protein X
component,
mitochondrial
ODPX MOUSE 2 4 54.3 7.6 66 0.42
35 Tropomyosin
alpha-1 chain
TPM1 MOUSE 15 43 32.7 4.7 302 0.40
36
Electron transfer
flavoprotein subunit
alpha,
mitochondrial
ETFA MOUSE 8 33 35.3 8.6 235 0.40
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Table 1: Continued.
Spot No. Protein name Protein ID
Peptides
matched
Coverage
(%)
Molecular
mass (kDa)
Isoelectric
point (pI)
Mascot score Fold change
37
60 kDa heat shock
protein, Hsp60,
mitochondrial
CH60 MOUSE 12 32 61.1 5.9 346 0.40
38
Isocitrate
dehydrogenase
[NAD] subunit
alpha,
mitochondrial
IDH3A MOUSE 9 29 40.1 6.3 164 0.40
39 Actin, alpha cardiac
muscle 1
ACTC MOUSE 12 31 42.3 5.2 317 0.39
40
NADH
dehydrogenase
[ubiquinone]
flavoprotein 2,
mitochondrial
NDUV2 MOUSE 6 29 27.6 7.0 370 0.39
41
Voltage-dependent
anion-selective
channel protein
VDAC1
VDAC1 MOUSE 10 29 32.5 8.6 292 0.39
42
Isocitrate
dehydrogenase
[NAD] subunit
alpha,
mitochondrial
IDH3A MOUSE 13 39 40.1 6.3 376 0.39
43 Desmin DESM MOUSE 30 50 53.5 5.2 1184 0.39
44
60 kDa heat shock
protein, Hsp60,
mitochondrial
CH60 MOUSE 25 38 61.1 5.9 842 0.37
45 Actin, alpha cardiac
muscle 1
ACTC MOUSE 10 26 42.3 5.2 276 0.36
46 Actin, alpha cardiac
muscle 1
ACTC MOUSE 4 14 42.3 5.2 88 0.36
47 Desmin DESM MOUSE 15 37 53.5 5.2 349 0.36
48
Myosin regulatory
light chain 2, atrial
isoform
MLRA MOUSE 9 57 19.6 4.8 299 0.36
49
Fatty acid-binding
protein, FABP-3,
heart
FABPH MOUSE 12 61 14.8 6.1 425 0.35
50
ATP synthase
subunit beta,
mitochondrial
ATPB MOUSE 18 40 56.3 5.2 1093 0.35
51 Cytochrome c
oxidase subunit 5A
COX5A MOUSE 7 28 16.3 6.1 286 0.35
52 Desmin DESM MOUSE 26 62 53.5 5.2 1657 0.35
53 Myosin light chain 3 MYL3 MOUSE 6 41 22.5 5.0 90 0.35
54 Desmin DESM MOUSE 12 30 53.5 5.2 431 0.33
55
ATP synthase
subunit d,
mitochondrial
ATP5H MOUSE 3 21 18.8 5.5 48 0.33
56 Actin, alpha cardiac
muscle 1
ACTC MOUSE 16 40 42.3 5.2 598 0.32
57 Cytochrome b-c1
complex
QCR1 MOUSE 12 27 53.4 5.8 330 0.32
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Table 1: Continued.
Spot No. Protein name Protein ID
Peptides
matched
Coverage
(%)
Molecular
mass (kDa)
Isoelectric
point (pI)
Mascot score Fold change
58 Desmin DESM MOUSE 36 68 53.5 5.2 1289 0.32
59 Tropomyosin
alpha-1 chain
TPM1 MOUSE 21 46 32.7 4.7 605 0.32
60 Actin, alpha cardiac
muscle 1
ACTC MOUSE 18 59 42.3 5.2 450 0.31
61 Myosin light chain 3 MYL3 MOUSE 11 63 22.5 5.0 231 0.30
62
Myosin regulatory
light chain 2,
ventricular/cardiac
muscle isoform
MLRV MOUSE 13 73 18.9 4.9 118 0.29
63 Cytochrome b-c1
complex
QCR1 MOUSE 12 31 53.4 5.8 342 0.29
64 Actin, alpha cardiac
muscle 1
ACTC MOUSE 7 36 42.3 5.2 160 0.29
65
Myosin regulatory
light chain 2,
ventricular/cardiac
muscle isoform
MLRV MOUSE 7 46 18.9 4.9 354 0.29
66 Actin, alpha cardiac
muscle 1
ACTC MOUSE 4 24 42.3 5.2 91 0.28
67 Actin, alpha cardiac
muscle 1
ACTC MOUSE 17 62 42.3 5.2 294 0.27
68 Adenylate kinase
isoenzyme 1
KAD1 MOUSE 5 31 21.6 5.7 174 0.26
69
ATP synthase
subunit beta,
mitochondrial
ATPB MOUSE 4 21 56.3 5.2 92 0.26
70 Myosin regulatory
light chain 2
MLRA MOUSE 6 47 19.6 4.8 168 0.25
71 Actin, alpha cardiac
muscle 1
ACTC MOUSE 18 61 42.3 5.2 302 0.25
72
ATP synthase
subunit d,
mitochondrial
ATP5H MOUSE 5 36 18.8 5.5 69 0.25
73
ATP synthase
subunit beta,
mitochondrial
ATPB MOUSE 18 51 56.3 5.2 640 0.25
74
ATP synthase
subunit beta,
mitochondrial
ATPB MOUSE 25 71 56.3 5.2 1102 0.25
75 Actin, alpha cardiac
muscle 1
ACTC MOUSE 6 16 42.3 5.2 119 0.25
76 Myosin light chain 3 MYL3 MOUSE 6 30 22.5 5.0 99 0.25
77
ATP synthase
subunit beta,
mitochondrial
ATPB MOUSE 24 70 56.3 5.2 871 0.24
78
Myosin light chain
2,
ventricular/cardiac
MLRV MOUSE 11 77 18.9 4.9 206 0.24
79 Peroxiredoxin-6 PRDX6 MOUSE 3 19 24.9 5.7 102 0.19
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Figure 2: 2D gel electrophoretic analysis of the dystrophic heart using the pH 6–11 range. Shown are Cy3-labelled gels of the soluble fraction
from normal (a) and dystrophic MDX (c) cardiac muscle, as well as Cy5-labelled gels containing pooled standards ((b), (d)). Representative
fluorescent DIGE gels with electrophoretically separated proteins are shown for the pH 6–11 range. The pH-values of the first dimension gel
system and molecular mass standards (in kDa) of the second dimension are indicated on the top and on the left of the panels, respectively.
a lack of antibody specificity, proteomic findings on an
individual 2D protein spot sometimes do not correlate
fully with the findings from biochemical or cell biological
analyses of total protein cohorts. These apparent differences
in the fate of individual subspecies of a protein versus the
total protein population probably reflect the complexity of
disease-related changes in the cardiac proteome. Figure 5(a)
shows a Coomassie-stained gel of crude preparations from
normal and dystrophic hearts and illustrates that no major
differences exist in the overall protein expression levels
between the two different phenotypes. The immunoblot
analysis of laminin, desmin, the slow/cardiac myosin heavy
chain and succinate dehydrogenase revealed no major dif-
ferences in the concentration of these abundant cardiac
proteins in normal versus MDX specimens (Figures 5(b)–
5(d) and 5(g)). In contrast, immunoblotting of the enzyme
adenylate kinase AK1, the fatty acid transporter FABP3,
isocitrate dehydrogenase, ATP synthase and porin isoform
VDAC1 showed a reduced abundance in MDX preparations
(Figures 5(e), 5(f), 5(h)–5(j)). Figure 6 summarizes the
statistical evaluation of the immunoblot survey in a graphical
presentation. The reduced expression of adenylate kinase
isoform AK1, fatty acid binding protein FABP3, isocitrate
dehydrogenase ICDH, porin isoform VDAC1, and ATP
synthase was found to be statistically significant, while the
concentration of desmin, myosin heavy chain and succinate
dehydrogenase was shown not to be significantly different
between normal and dystrophic preparations. Thus the
overall isoform population of succinate dehydrogenase and
desmin does not appear to be reduced in dystrophinopathy,
although the above-described DIGE analysis showed a lower
level of distinct subspecies of these cardiac elements. In gen-
eral, the immunoblotting results support the main findings
from our DIGE analysis of normal versus dystrophic heart
tissue and demonstrate independently that the deficiency in
dystrophin has a profound effect on the expression pattern of
the cardiac protein complement.
3.5. Immunofluorescence Analysis of Dystrophic Heart Muscle.
Since the DIGE analysis of the normal versus the dystrophic
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Figure 3: DIGE analysis of normal versus dystrophic MDX cardiac muscle. Shown are Cy5-labelled master gels of the soluble fraction
from mouse heart muscle, covering both the pH 4–7 (a) and pH 6–11 (b) range. Protein spots with a drastically different expression level
are marked by circles and are numbered 1 to 79. See Table 1 for a detailed listing of cardiac muscle proteins with a changed abundance in
dystrophin-deficient tissue. The pH-values of the first dimension gel system and molecular mass standards (in kDa) of the second dimension
are indicated on the top and on the left of the panels, respectively.
MDX heart has revealed changes in a variety of mitochon-
drial components, it was important to determine whether
this alteration was due to a reduced number of mitochondria
in the dystrophic heart or internal abundance changes in
the mitochondrial protein complement. Figure 7 shows
representative results from an immunofluorescence survey of
mitochondrial content, nuclei and cardiac marker proteins
in dystrophic tissue. Cryosections of MDX tissue showed a
complete absence of the dystrophin isoform Dp427 (Figures
7(c), 7(d)), confirming the mutant status of the dystrophic
hearts used in this study. DAPI staining revealed 229± 6
and 270±18 nuclei per examined tissue section in normal
versus dystrophic tissue sections, respectively (Figures 7(a),
7(b)). The slight increase of nuclei in MDX preparations
was not statistically significant (n = 4). Thus the proteomic
finding of a dystrophy-dependent increase in lamin-A/C is
therefore not directly related to a drastic change in the
number of nuclei per cardiac tissue unit. Fluorescent labeling
of mitochondria with the MitoTracker dye CMXRos showed
a characteristic internal staining pattern in cardiac fibres
(Figures 7(e)–7(h)). Fluorescent intensity values of 1470±36
and 1384 ± 40 for normal versus MDX preparations were
found not to be significantly different (n = 4). Hence,
lower levels of mitochondrial enzymes do not seem to be a
consequence of a drastic decrease in mitochondrial density in
the dystrophic MDX heart. In addition, confocal microscopy
was employed for the localization of cardiac marker proteins.
The immunofluorescence labeling of desmin (Figures 7(i)–
7(l)), prohibitin (Figures 7(m)–7(p)) and succinate dehy-
drogenase (Figures 7(q)–7(t)) was shown to be comparable
between control and pathological samples. The microscop-
ical localization of desmin and succinate dehydrogenase
revealed unexpectedly not a decrease of these proteins in
dystrophic tissue sections, as found by DIGE analysis. Hence,
although distinct subspecies of certain cardiac proteins are
affected in X-linked muscular dystrophy as determined by
mass spectrometry-based proteomics, the overall isoform
complement of these elements is not drastically altered. This
indicates that no major differences exist in the expression
levels of desmin-containing intermediate filament structures
and the population of cardiac mitochondria in normal versus
dystrophin-deficient cells.
4. Discussion
In order to enhance our knowledge of the molecular
pathogenesis of cardiomyopathy linked to X-linked muscular
dystrophy, a detailed proteomic profiling of the dystrophic
heart was carried out. The biochemical establishment of a
comprehensive disease-specific biomarker signature for X-
linked muscular dystrophy is crucial for (i) the development
of superior diagnostic methods, (ii) the identification of
new therapeutic targets to address cellular alterations down-
stream of the primary abnormality in dystrophin, and (iii)
the evaluation of new treatment approaches to counter-
act the various pathological aspects of dystrophinopathy
[41]. The proteomic profiling of MDX skeletal muscle
has recently established altered expression levels of soluble
proteins involved in nucleotide metabolism, Ca2+-handling
and the cellular stress response [42–45]. The mass spec-
trometric analysis of experimental exon skipping therapy
revealed a partial reversal of dystrophic changes in these
new signature molecules [60], illustrating the potential of
proteomic technology to decisively enhance the capabilities
of biomedical research into the molecular mechanisms that
underlie neuromuscular disorders. In contrast to skeletal
muscle, very little is known about the global pathobiochem-
ical mechanisms that lead to cardiac complications in the
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Figure 4: Decreased expression of key proteins in the dystrophin-deficient MDX heart. Shown are expanded views of 2-D gels of normal
versus dystrophic MDX heart tissue. Shown are the AK1 isoform of adenylate kinase, ATP synthase, DJ1-protein, fatty acid binding protein
FABP3, porin isoform VDAC1, stress protein Hsp60, isocitrate dehydrogenase (ICDH), myosin light chain MLC2, succinate dehydrogenase
(SDH) and prohibitin. The position of 2-D spots representing distinct mitochondrial proteins is indicated by arrowheads on the right.
dystrophin-deficient organism. Here, we have successfully
applied the fluorescent DIGE method to the large-scale
analysis of the dystrophic heart. MS-based proteomics clearly
revealed a drastic decrease in key metabolic, regulatory
and contractile proteins, as well as components of the
cytoskeleton and the cellular stress response. The pie chart
of Figure 8 summarizes the apparent functions of DIGE-
identified proteins with a differential expression in normal
versus dystrophin-deficient heart muscle.
The DIGE analysis presented here showed a moder-
ate increase in lamin-A/C, which might improve nuclear
stability, chromatin structure and gene expression in the
dystrophic heart. Since comparative DAPI staining indicates
comparable numbers of nuclei in normal versus dystrophic
fibres, tissue scarring is probably not responsible for an
increase in the number of nuclei per tissue unit. Therefore,
the elevated lamin concentration does not appear to be
associated with increased numbers of nuclei. Cardiac lamins
make up the matrix that is located close to the inner nuclear
membrane. Interestingly their deficiency causes familial
dilated cardiomyopathy [61]. The only drastic increase in
a cardiac protein was the 4-fold change in the expression
of nucleoside diphosphate kinase B. Nucleoside diphosphate
kinases are key regulatory enzymes involved in intracellular
di- and tri-phosphonucleoside homeostasis. Their cellular
functions are critical for signaling, proliferation, differenti-
ation and bioenergetics [62], which suggests that the up-
regulation of one of their isoforms could be considered a
counter measure of the dystrophin-deficient heart to stabilize
essential cellular functions in severely stressed muscle cells.
In contrast to the 4-fold increase in nucleoside diphosphate
kinase, our proteomic screening demonstrated a massive
decrease in a variety of cardiac proteins in the MDX
heart. The dystrophinopathy-associated loss in numerous
key proteins, which belong to different cellular pathways
and functions in the heart, agrees with the severity of the
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Figure 5: Immunoblotting survey of cardiac proteins in dystrophic tissue. Shown is a Coomassie-stained gel (a) and corresponding
immunoblots with expanded views of immuno-decorated bands ((b)–(j)). Immunoblotting was performed with antibodies to laminin
(b), desmin (c), slow/cardiac myosin heavy chain ((d); MHCs), adenylate kinase isoform AK1 (e), porin isoform VDAC1 (f), succinate
dehydrogenase ((g); SDH), fatty acid binding protein FABP3 (h), isocitrate dehydrogenase ((i); ICDH), and ATP synthase (j). See Figure 6
for the statistical evaluation of this immunoblotting survey of cardiac proteins. Molecular mass standards (in kDa) are indicated on the left
of panel (a). Lanes 1 and 2 represent normal and dystrophic muscle extracts from control and MDX mice, respectively.
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Figure 6: Graphical presentation of the immunoblot analysis of cardiac marker proteins in dystrophic tissue. Shown is the graphical
presentation of the statistical evaluation of immuno-decoration using antibodies to adenylate kinase isoform AK1 (a), fatty acid binding
protein FABP3 (b), isocitrate dehydrogenase ICDH (c), porin isoform VDAC1 (d), ATP synthase (e), desmin (f), slow/cardiac myosin heavy
chain MHCs (G) and succinate dehydrogenase SDH (H). The comparative blotting was statistically evaluated using an unpaired Student’s
t-test (n = 5; ∗P < .05; ∗∗P < .01). The concentration of desmin, myosin heavy chain and succinate dehydrogenase was found not to be
significantly different between normal and dystrophic preparations. Lanes 1 and 2 represent normal and dystrophic muscle extracts from
control and MDX mice, respectively.
cardiomyopathic complications observed in aged MDX mice
and DMD patients [13–15].
Key proteins involved in cardiac contraction, cytoskeletal
integrity, nucleotide metabolism, cellular stress response,
mitochondrial metabolism, and fatty acid transportation
were shown to be affected by a deficiency in cardiac
dystrophin. Interestingly, Braun et al. [63] could show an
altered integration of mitochondria and ATPases in slow-
twitching MDX muscles. The coupling between mitochon-
drial creatine kinase and the adenine nucleotide translocase
system appears to be weakened in dystrophin-deficient fibres.
This seems to result in a rearrangement of intracellular
energy transfer in dystrophic muscle [63]. The 6-fold
decrease in peroxiredoxin-6 may have drastic consequences
for the capability of the dystrophic heart to counter-act the
detrimental effects of stressors. Peroxiredoxin-6 is a crucial
enzyme that protects cells from oxidative stress [64]. In
analogy to the reduced concentration of this antioxidant
enzyme in cardiac MDX tissue, the decrease in the small
heat shock protein Hsp27, as well as Hsp60 and DJ-1
protein, also agrees with an impaired cellular stress response
in muscular dystrophy-associated cardiomyopathy. Small
heat shock proteins provide crucial chaperone function in
striated muscles and are upregulated in the heart following
exercise training [65]. An impaired stress response could
result in the detrimental aggregation of misfolded proteins
causing cellular dysfunction in the dystrophic heart. The
dystrophinopathy-associated decrease in valsolin-containing
protein VCP might also impair cardiac function. VCP
belongs to the AAA-ATPase superfamily and is involved in
various cellular functions such as membrane fusion and cell-
cycle control, as well as protein degradation through the
ubiquitin-proteasome pathway [66].
The DIGE analysis of the MDX heart presented here has
clearly shown a severely altered concentration of numerous
key players involved in cardiac contraction and cytoskeletal
organization. In contrast to comparable levels of myosin
heavy chain, other critical contractile proteins are affected
by the lack of dystrophin. The biomolecules that form
the thick and thin filaments of the basic contractile units
exist in a complex arrangement of myosin heavy chains,
myosin light chains, and actins. Muscle myosin consists
of a hexameric arrangement that is formed by two heavy
chains and two pairs of myosin light chains. Changes in
myosin light chains have been implicated in severe cardiac
impairments, such as familial hypertrophic cardiomyopathy
[67]. Hence, the reduction in the cardiac isoform of myosin
light chain MLC2, myosin light chain MLC3, and cardiac
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Figure 7: Immunofluorescence survey of mitochondrial content, nuclei and cardiac marker proteins in dystrophic tissue. Confocal
microscopy was used for the localization of nuclei, mitochondria and cellular markers in normal ((a), (c), (e), (g), (i), (k), (m), (o), (q),
(s)) versus dystrophic MDX ((b), (d), (f), (h), (j), (l), (n), (p), (r), (t)) heart cryosections. Shown is labeling of nuclei with the DNA binding
dye DAPI ((a), (b)), visualization of mitochondria with the red-fluorescent MitoTracker dye CMXRos ((e)-(h)), and antibody labeling of
full-length dystrophin isoform Dp427 ((c), (d)), desmin DES ((i)-(l)), prohibitin PRO ((m)-(p)) and succinate dehydrogenase SDH ((q)-
(t)). The number of nuclei and the labeling of mitochondria with the MitoTracker dye CMXRos were found not to be significantly different
between normal and dystrophic preparations. The bars in panels (a) to (t) equal 30 μm.
alpha-actin might have a severe impact on the contractile
apparatus in the dystrophic heart. Contractile weakness
observed in dystrophinopathy could be directly related to
the altered concentration of myosin light chains and actin.
Cardiac muscle cells are activated by Ca2+-binding to TnC-
subunit of troponin and is regulated by the interactions of
tropomyosin and troponin in the thin filament. Thus, the
observed reduction of alpha-1 tropomyosin in the MDX
heart might also be of pathophysiological significance. Since
the molecular coupling between the myosin head structure
and actin filaments, in the presence of ATP, represents
the major step that underlies the sliding of thin filaments
past thick filaments, abnormal concentrations of regulatory
proteins may result in impaired patterns of sarcomeric
shortening.
In addition, a close connection exists between the con-
tractile apparatus, the membrane-associated actin network
and the cytoskeleton. Intermediate filaments are of crucial
importance for the mechanical integrity and elasticity of
contractile fibres. Although proteomics showed that the
expression levels of distinct subspecies of desmin were
reduced in dystrophic preparations, confocal microscopy
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Figure 8: Overview of biological functions of DIGE-identified proteins with an altered expression in dystrophic heart muscle. The pie
chart summarizes the apparent functions of DIGE-identified proteins with a differential expression in normal versus dystrophin-deficient
MDX heart muscle. A large proportion of these affected proteins belong to cardiac mitochondria including metabolic elements of oxidate
phosphorylation, the citric acid cycle and fatty acid transportation, as well as proteins associated with the contractile apparatus, the cellular
stress response, and the cytoskeletal network.
and immunoblotting revealed that the overall population
of desmin isoforms is comparable between normal and
MDX heart. However, the deficiency in cardiac dystrophin
appears to trigger a concomitant reduction in the density
of myozenin-2 and vimentin. Myozenin-2 belongs to the
calsarcin family of proteins, a new type of sarcomeric
calcineurin-binding protein [68]. Vimentin is a crucial
intermediary filament protein and plays a key role in
cytoskeletal network formation. The abnormal expression
levels of these proteins might therefore cause disturbed
interfilament interactions and impaired cystoskeletal arrays,
thereby causing cellular instability in the dystrophic heart.
One of the most important findings of this mass
spectrometry-based proteomic study is the drastically
reduced concentration of numerous mitochondrial proteins
and metabolic transporters. Since mitochondria represent
the primary site for energy generation via oxidative phos-
phorylation [69], a reduction in elements belonging to the
oxidative phosphorylation complexes, the citric acid cycle
and ion homeostasis will have a profound influence on
the bioenergetic status of the dystrophic heart. Cardiac
mitochondria are involved in intermediary metabolism, cell
cycle progression, calcium signaling and the regulation of
apoptosis, as well as the production of heme and iron-sulfur
clusters. Proteomic investigations suggest that approximately
1,500 different mitochondrial proteins exist [70]. Previous
studies have shown that altered expression levels within the
mitochondrial proteome influence many aspects of normal
development, diseases and the aging process. With respect to
the heart, mitochondrial dysfunction appears to be associ-
ated with numerous pathologies such as congestive heart fail-
ure, ischaemia reperfusion injury and cardiomyopathy [71].
Therefore, the reduced expression of many mitochondrial
proteins associated with the matrix, outer membrane and
inner membrane system suggests an impaired metabolism
in the dystrophic heart. Reduced expression levels within
the mitochondrial proteome appear to affect the functioning
of the mitochondrial ATP synthase, isocitrate dehydroge-
nase, NADH dehydrogenase, oxoglutarate dehydrogenase,
isovaleryl-CoA dehydrogenase, cytochrome c oxidase and the
cytochrome b-c complex, all critical elements involved in
mitochondrial function in the heart [69]. This agrees with a
previous study by Zhang et al. [72], who reported a decreased
citrate synthase activity in the MDX heart. Although a certain
degree of cellular scarring and the infiltration of fatty and
connective tissue may reduce the number of contractile fibres
in the dystrophic heart, as previously shown by histochemical
analysis [72], this does not appear to drastically alter the
density of muscle-associated mitochondria. The confocal
microscopy analysis shown in this report suggests no major
changes in the number of mitochondria between normal and
dystrophic heart muscle tissue, as judged by labeling with
the established chloromethyl-X-rosamine MitoTracker dye
which is concentrated inside mitochondria by their negative
membrane potential [53–55].
Our DIGE analysis revealed that individual protein
spots representing electron-transferring flavoprotein showed
both increased and decreased abundance. Electron transfer
flavoprotein ubiquinone oxidoreductase provides a crucial
link between electrons derived from fatty acid oxidation and
certain amino acids to the main respiratory chain system of
mitochondria [73]. The differential effect on different iso-
forms of this protein is difficult to interpret, but dystrophin
deficiency must affect distinct subspecies of this metabolic
element with differing post-translational modifications in a
dissimilar way. The observed reduction in the rate-limiting
enzyme pyruvate dehydrogenase could have severe impact
on the utilization of energy carriers and thereby impair the
overall bioenergetics of the MDX heart. Isoforms of cardiac
prohibitin are present in the inner mitochondrial membrane
and are responsible for the efficient assembly of mitochon-
drial respiratory chain enzymes and perform chaperone
18 Journal of Biomedicine and Biotechnology
activity. Interestingly, a proteomic survey of mitochondrial
proteins in cardiomyocytes from chronic stressed rats has
shown a drastic increase in prohibitin [74]. Although the
overall complement of prohibitin isoforms is not drastically
affected in muscular dystrophy, a reduced expression of
distinct subspecies of prohibitin in the dystrophic heart
might be associated with an impaired cellular stress response.
The only affected glycolytic enzyme appears to be enolase,
indicating that mitochondrial metabolism is more severely
affected than glycolysis in dystrophy-related cardiomyopathy.
Interestingly, the abundance of the extracellular and intra-
cellular fatty acid transporters albumin and FABP-3, which
are considered limiting factors of oxidative metabolism in
striated muscles, is decreased in the dystrophin-deficient
heart. Thus, dystrophic heart cells would be starved of
essential fuel supplies, which might trigger a decline in
contractile strength. A mitochondrial receptor present in the
outer mitochondrial membrane was identified as a porin
isoform that forms voltage-dependent anion channels. These
ion channels belong to a family of pore-forming proteins
that provide large membrane-spanning aqueous channels
[75]. The decreased concentration in the porin transport
protein would indicate a dystrophy-associated decrease in
mitochondrial function and abnormal ion homeostasis.
In contrast to a recent combined metabolomic and
proteomic study of the MDX heart [46], and in agreement
with two comprehensive proteomic studies on MDX skeletal
muscle [42, 45], we could show here a decreased abundance
of the AK1 isoform of adenylate kinase. The proteomic find-
ing was clearly verified by immunoblot analysis. Nucleotide
metabolism, involving adenylate kinase and creatine kinase
appears to be disturbed in the dystrophic MDX heart, and
this finding might be useful for the future development
of a comprehensive biomarker signature of cardiomyopathy
associated with muscular dystrophy. Overall, our DIGE-
based screening of the soluble proteome from dystrophic
MDX hearts has revealed a severely perturbed protein
expression pattern due to deficiency in dystrophin. The
observed changes in essential proteins involved in cardiac
contraction, mitochondrial metabolism, the cellular stress
response and nucleotide metabolism might be useful for the
future improvement of differential diagnostic procedures,
the assessment of cardiac disease progression in X-linked
muscular dystrophies, the identification of novel therapeutic
targets to treat cardiomopathic complications in Duchenne
muscular dystrophy, and the evaluation of novel treatment
strategies to counter-act the loss in cardiac dystrophin.
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